Acurx Pharmaceuticals (ACXP) Cash from Financing Activities (2020 - 2026)

Acurx Pharmaceuticals (ACXP) has 6 years of Cash from Financing Activities data on file, last reported at $3.1 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 3.93% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.8 million (up 111.09% YoY) and the FY2025 annual result came in at $10.6 million, up 60.78% from the prior year.
• Cash from Financing Activities grew to $3.1 million in Q1 2026, from $2.8 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $4.6 million in Q4 2023 to a low of -$1.0 in Q4 2022.
• A 5-year average of $2.3 million and a median of $2.8 million in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities soared 461963800.0% — and 2024, when it slumped 95.79%.
• Tracing ACXP's Cash from Financing Activities over 5 years: stood at -$1.0 in 2022, then soared by 461963800.0% to $4.6 million in 2023, then tumbled by 95.79% to $194547.0 in 2024, then soared by 1356.74% to $2.8 million in 2025, then grew by 9.6% to $3.1 million in 2026.
• The last three Cash from Financing Activities figures came in at $3.1 million (Q1 2026), $2.8 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.